Global research trends and hotspot evolution analysis of immunotherapy for allergic rhinitis: a multi-dimensional exploration based on bibliometrics Authors: Jun Wu, Youwei Bao, Qi Chen, Xinhua Zhu Published: 2026 ABSTRACT Highlights•First bibliometric analysis of global allergic rhinitis immunotherapy research.•Triple shift: therapy→biologics, diagnostics→molecular, care→integrated.•Anti-IgE (omalizumab) and anti-IL-4Rα (dupilumab) are key biologics.Keywords: Rhinitis, Allergic, Immunotherapy, Biological products, Bibliometrics, Precision medicine Introduction Allergic Rhinitis (AR) is a highly prevalent chronic inflammatory disease worldwide, affecting the quality of life of 10%-40% of the global population, with its incidence continuing to rise. The condition not only causes typical symptoms such as nasal congestion, rhinorrhea, and sneezing but also has a comorbidity rate with asthma as high as 40%, imposing a substantial socioeconomic burden.1 Allergen Immunotherapy (AIT) is recognized as the only etiological treatment strategy capable of altering the natural course of AR, due to its ability to induce long-term antibody production in patients and suppress the allergic response process at the immune level.2, 3, 4 Over the past three decades, the field of AR immunotherapy has undergone revolutionary changes, evolving from traditional Subcutaneous Immunotherapy (SCIT) to Sublingual Immunotherapy (SLIT), and more recently, to the emergence of biologics and novel interventional techniques.5, 6, 7, 8 However, given the rapidly iterating technological approaches and intricate mechanistic research, there is a pressing need to systematically map the knowledge structure, evolution of research hotspots, and collaboration networks in this field. Traditional article reviews, reliant on subjective screening, struggle to quantify trends and reveal cross-disciplinary connections. Therefore, this study utilizes the Web of Science database and analytical tools such as VOSviewer, CiteSpace, and the R package bibliometrix to analyze global trends, key hotspots, and research trajectories in AR immunotherapy. The aim is to guide future research directions, address gaps in the understanding of immunotherapy's role in AR management, and provide a scientific basis for optimizing prevention and control strategies while advancing the translation of precision medicine.9, 10, 11 Methods Data sources and retrieval strategies Data source and search strategy A systematic article search was conducted using the Web of Science Core Collection, including the Science Citation Index Expanded (SCI-Expanded) and the Social Sciences Citation Index (SSCI) databases. The search strategy was as follows: TS = (("allergic rhiniti" OR "hay fever" OR "seasonal allerg" OR "perennial allerg") AND ("immunotherap" OR "AIT" OR "desensitization" OR "allergen immunotherap" OR "SLIT" OR "sublingual immunotherap" OR "SCIT" OR "subcutaneous immunotherap" OR "intralymphatic immunotherap" OR "biologic agent" OR "monoclonal antibod" OR "dupilumab" OR "omalizumab" OR "mesenchymal stem cell*" OR "MSC therapy")). Article screening and inclusion criteria To minimize potential bias from routine database updates, all searches and data downloads were completed within a single day on 2025.10.20. The preliminary publication time frame was set from January 1, 2010, to December 31. The initial search yielded 3,117 publications. Following manual screening to remove irrelevant records, 2,598 publications from the last 15-years were retained. After further filtering by document type and removal of duplicates, 2,470 publications were ultimately included for analysis (for example, meeting summaries, editorials, letters, etc.). This final dataset comprised 1,778 original articles and 692 reviews, providing a robust foundation for subsequent bibliometric analysis (Fig. 1A).12 (A) Article search workflow for this study. (B) Annual publication trends. (C) Geographical distribution of corresponding authors by country (based on publication statistics). (D) Geographic distribution of the top 20 countries/regions with most publications by corresponding authors. (E) Country Cooperation Network. (F) Top 10 institutions by publication volume. (G) Annual publication volume of institutions. (H) Visualization of institutional collaboration networks. (I) Top 10 journals by publication volume. (J) Annual publication volume of journals. (K) Visualization of journal collaboration networks. Data analysis Visualization network construction: VOSviewer 1.6.18 was used to generate national/institutional cooperation network and keyword co-occurrence clustering. Evolution path analysis: CiteSpace 6.2.R4 was used for keyword emergence detection and time zone mapping. Impact evaluation: combined with the Citation frequency (Citation), H-index and the proportion of highly cited papers (Top 1%); Statistical methods: Pandas and Matplotlib libraries in Python 3.10 were used to complete the trend fitting and statistical test. All software and tools mentioned are publicly available versions, with no proprietary or restricted licenses utilized. Results Publication trend analysis This study analyzed 2,470 publications on AR immunotherapy from 2010 to 2024, contributed by 9,311 researchers from 1,838 institutions across 83 countries. The annual publication output demonstrated a trend of steady expansion, with the number of articles increasing from 110 in 2010 to a peak of 233 in 2024 (Fig. 1B). The distribution of publications by country, based on the affiliations of corresponding and first authors, highlighted the leading contributions of China (437 publications) and the United States (427 publications). Other high-output countries included Italy (200) and Germany (197) (Fig. 1C‒D). The international collaboration network further illustrates the central role these countries play in global research efforts (Fig. 1E). Core institutions and cooperation networks The most prolific institutions were Humboldt University of Berlin, Free University of Berlin, and Imperial College London. These leading contributors also maintained a dense collaboration network, underscoring the role of inter-institutional partnerships in advancing this field. Humboldt University of Berlin was the most productive institution with 190 publications (Fig. 1F), followed by Imperial College London (188), Free University of Berlin (187), Charité – Universitätsmedizin Berlin (166), and Université de Montpellier (146). Within the collaboration network, frequent cross-regional partnerships among numerous institutions were observed, where a higher number of connections indicates a greater level of collaborative activity (Fig. 1F‒H). Distribution of high impact journals The 2,470 analyzed publications were disseminated across 437 academic journals. The top 10 most productive journals collectively published 781 articles, accounting for 31.62% of the total output. Among these, Allergy (154 articles), the Journal of Allergy and Clinical Immunology (113), and the International Archives of Allergy and Immunology (79) emerged as the three most influential journals, underscoring their pivotal role in allergy research. Fig. 1I presents the annual publication trends for these key journals, while Fig. 1J displays their total citation counts. Furthermore, the journal co-citation network, illustrated in Fig. 1K, reveals the intellectual relationships and knowledge flow between these publications. Authors and co-cited authors Analysis of the author collaboration network identified the leading contributors. The most prolific author was Oliver Pfarr (67 publications), followed by Ludger Klimek (55 publications) and Stephen R. Durham (50 publications). Furthermore, the examination of co-authorship networks (Fig. 2B The red line indicates collaboration between authors), annual publication output, and H-index metrics collectively underscores their central influence and sustained productivity in AR immunotherapy research (Fig. 2A‒F). (A) Top 10 authors by publication volume. (B) Author collaboration network map. (C) Co-author network. (D) Annual publication details of top 10 authors. (E) Local citation H-index for authors. (F) Most Local Cited Authors. (G) Most Global Cited Documents. (H) Citation network relationships. (I) Citation network of the article. Article analysis Analysis of the included article identified the most frequently cited works. The three most cited publications were Brozek JL et al. (2010, J Allergy Clin Immunol), Cox L et al. (2011, J Allergy Clin Immunol), and Greiner AN et al. (2011, Lancet), underscoring the influential role of these journals in the field. The study by Brozek JL et al. (2010) demonstrated the strongest impact, with a total of 1,204 citations, 75.25 citations per year, and a normalized citation count of 22.14. Fig. 2H presents the direct citation network of these publications, while Fig. 2I visualizes their co-citation relationships. Keywords co-occurrence and burst analysis Keyword co-occurrence analysis extracted 6,073 terms from the publications. The most frequent keywords were “allergic rhinitis” (1,241 occurrences), “asthma” (1,052), “subcutaneous immunotherapy” (726), “immunotherapy” (642), and “efficacy” (534) (Fig. 3A‒B). The thematic evolution map (Fig. 3C) illustrates a clear trajectory of research priorities from 2010 to 2024. Early studies focused on extending traditional Allergen Immunotherapy (AIT) and establishing its standardization and safety. The research paradigm has since evolved from basic mechanism exploration and clinical efficacy validation towards personalized treatment (for children/specific allergens), with current emphasis shifting to holistic disease management, encompassing quality of life and economic outcomes (Fig. 3A‒E). (A) Keyword Cloud. (B) Keyword Tree Graph. (C) Trend Topics. (D) Word's Frequency Over Time. (E) Timeline clustering analysis based on Citespace. (F) Factor Analysis Results. (G) Keyword Clustering Analysis Results. (H) Top 20 Keywords with the highest citation count. Cluster analysis of keywords helped identify the field's major research themes. The six primary clusters, each representing a unique focus area, are as follows (Fig. 3G): Cluster 1 (Pharmacotherapy & Alternative Medicine): Encompasses drug treatments (antihistamines, biologics), desensitization therapies, and alternative treatments (acupuncture) for allergic diseases like asthma and atopic dermatitis, with a focus on disease control across age groups, particularly adolescents. Cluster 2 (Immunological Mechanisms): Focuses on the immunologic basis of allergic diseases, including immune cells (B-cells, basophils, dendritic cells), cytokines, signaling pathways, and disease mechanisms like the atopic march. Cluster 3 (Clinical AIT Trials): Centers on AIT, emphasizing its efficacy, safety, adherence, and cost-effectiveness in pediatric populations, primarily through methodologies like randomized controlled trials. Cluster 4 (Molecular Allergology & Diagnostics): Delves into the molecular characteristics of specific allergens (pollen, dust mites, food allergens), cross-reactivity, diagnostic techniques (component-resolved diagnostics), and environmental factors (climate change). Cluster 5 (Guidelines & Integrated Management): Integrates international guidelines and consensus (ARIA, EAACI), long-term disease management strategies, health economics, patient-reported outcomes, and emerging digital health technologies (mHealth) for whole-life-cycle care. Cluster 6 (Patient Outcomes & Health Economics): Focuses on quality of life, specific treatment effects, and costs, considering the balance between healthcare burden and public health. Keyword burst detection further revealed the field's evolving trends (Fig. 3H). The top 20 keywords with the strongest citation bursts are shown. From 2010 to 2016, “specific immunotherapy” had the highest burst strength (14.77), followed by “sublingual immunotherapy” (13.82) and “respiratory allergy” (11.35). Notably, bursts for “innate lymphoid cells” and “severity” have persisted until the present, reflecting the latest research frontiers. Discussion This bibliometric analysis of AR immunotherapy research from 2004 to 2024 reveals a significant expansion in research output and a distinct evolution of hotspots. The United States, China, and European nations constituted the core driving forces behind this global endeavor, collectively propelling a paradigm shift from traditional therapies towards precision medicine.1,2,9,13 At the national and institutional levels, the United States maintained a leading position in frontier exploration, characterized by its high publication output and extensive international collaborative network. China followed closely, demonstrating rapid growth in research volume, with institutions like Capital Medical University making notable contributions. Europe, with Germany and Italy at its center, played a pivotal role in basic immunology and multi-center clinical trials, facilitated by the tightly-knit collaborative networks of institutions such as Humboldt University of Berlin and Imperial College London. Journal analysis identified Allergy and the Journal of Allergy and Clinical Immunology as the most influential knowledge-dissemination platforms in the field. These journals not only led in publication volume but also served as the primary venues for publishing highly-cited guidelines and groundbreaking clinical trials.14,15 The evolution of their published content directly mirrors the discipline's shift in focus from the standardization of immunotherapy towards the efficacy of biologics and personalized strategies. Concurrently, journals such as International Archives of Allergy and Immunology have played a critical bridging role by connecting fundamental immunological mechanisms with clinical translation.14, 15, 16, 17, 18, 19, 20, 21 The most influential scholars in this field, such as Oliver Pfaar, Ludger Klimek, and Stephen R. Durham, have established the foundation for AR immunotherapy and modern biologic therapies through their seminal work.22,24 Their research, spanning large-scale clinical trials to the dissection of immune mechanisms, has not only shaped the current treatment paradigm but has also charted a course for the future development of targeted therapeutics.22, 23, 24 Co-occurrence and burst analysis of keywords visually delineated the evolution of research hotspots. The persistent high frequency of keywords such as “allergic rhinitis”, “asthma”, “quality of life”, and “efficacy” underscores the long-standing focus on AR as a systemic disease and its impact on patients. In recent years, the explosive growth of keywords like “biologics”, “dupilumab”, and “omalizumab” signifies a decisive shift in research focus towards targeted therapy.25, 26, 27, 28, 29 Concurrently, the emergence of “innate lymphoid cells” and “severity” indicates a growing research direction aimed at precision diagnosis and understanding specific lymphocyte-driven immune mechanisms. Although the keyword strength of traditional “subcutaneous immunotherapy” and “sublingual immunotherapy” has diminished, their continued co-occurrence with terms like “safety” and “children” confirms that their optimization and safety assessment remain vital components of research. Notably, the research focus has shifted from popularizing therapies to achieving precision breakthroughs. In the early period (2010–2016), the keywords with the highest burst strength were “specific immunotherapy” (14.77) and “sublingual immunotherapy” (13.82), reflecting the standardized exploration of traditional AIT. In contrast, the recent rise of “dupilumab/omalizumab” (Cluster 1) and the persistent emergence of “innate lymphoid cells” (Fig. 3H) signify that biologics and immune mechanism research have become the new engine of the field. However, although the US and China lead in production volume, the density of institutional collaborations within these countries is weaker than in Europe (Fig. 1E), suggesting that regional synergistic potential has not yet been fully unleashed.8,30 In summary, research on AR immunotherapy is undergoing a profound transformation. Future research efforts should be dedicated to the following key directions: First, more real-world studies are needed to evaluate the long-term safety, efficacy, and cost-effectiveness of biologics, particularly in special populations such as children and patients with multiple comorbidities.31, 32, 33 Second, discoveries in basic immunology should be translated into clinical applications by exploring biomarkers that can predict treatment response, thereby enabling truly personalized therapy. Finally, there is an urgent need to integrate molecular diagnostics, targeted drugs, and digital health tools to establish a closed-loop management paradigm of “precise diagnosis-targeted intervention-dynamic monitoring”, alongside strengthening global research collaboration to collectively address AR as a worldwide health challenge. This study provides a comprehensive analysis of the AR immunotherapy landscape from 2010 to 2024; however, several limitations should be acknowledged. First, the reliance on a single database, Web of Science, may result in the omission of relevant studies published in non-English languages or regional journals (from Latin America or Africa). Second, the keyword clustering analysis is constrained by the sensitivity of the algorithm (VOSviewer resolution parameter = 1.0), which may have led to the merging of some nuanced, subtopics. Third, our bibliometric approach did not integrate findings from animal models with clinical data, such as cross-species validation of microbiome interventions, which warrants future investigation through multi-omics integrated analysis. Future studies could address these limitations by expanding the article search to include databases such as Scopus and PubMed, and by fostering interdisciplinary collaborations with, for instance, public health agencies. Notwithstanding these limitations, the extensive cross-disciplinary coverage and robust citation-tracking capabilities of the Web of Science database ensure a high degree of accuracy and efficiency for this type of medical research analysis, justifying its use as the primary data source. Conclusion Based on a bibliometric analysis of 2,470 publications from the Web of Science database (2010–2024), this study systematically elucidates global research trends and the evolution of hotspots in the field of AR immunotherapy. The core findings can be summarized as a “tripartite paradigm shift”. Therapeutically, the focus has moved from traditional SCIT/SLIT towards targeted biologics, notably omalizumab and dupilumab. Diagnostically, practices have advanced from the use of crude allergen extracts to molecular component-resolved techniques. In terms of disease management, the approach has evolved from isolated interventions to an integrated, full-cycle, closed-loop model that incorporates international guidelines (ARIA), digital health (mHealth), and patient-reported outcomes. Establishing and refining a “precise diagnosis-targeted intervention-dynamic management” framework is the essential pathway to advance AR care from symptomatic control towards disease modification. ORCID ID Qi Chen: 0009-0001-8207-5406 Xinhua Zhu: 0000-0002-3776-0287 Funding This research received no specific grant from funding agencies in public, commercial, or not-for-profit sectors. Data availability statement The authors declare that all data are available in repository. Declaration of competing interest The authors declare no conflicts of interest. Acknowledgements Not applicable. Edited by Dr C Chone. References Associated Data Data Availability Statement The authors declare that all data are available in repository.